By acting at the transcriptional level, PHIs maintain endogenous EPO levels within the physiological range preventing sudden and/or excessive Hgb level elevations potentially reducing the risk of cardiovascular events, thromboembolism and heart failure compared with current treatments (25). Here, EPO is linked to heart failure.